<DOC>
	<DOCNO>NCT00107809</DOCNO>
	<brief_summary>The primary objective study determine effectiveness PROVIGIL treatment , compare placebo treatment , child adolescent excessive sleepiness ( ES ) associate obstructive sleep apnea/hypopnea syndrome ( OSAHS ) , assess : - mean sleep latency Multiple Sleep Latency Test ( MSLT ) ( average 4 nap performed 0900 , 1100 , 1300 , 1500 ) last post baseline observation ( week 6 early termination ) - Clinical Global Impression Change ( CGI-C ) rating ES , last post baseline observation ( week 6 early termination ) .</brief_summary>
	<brief_title>Study PROVIGIL ® ( Modafinil ) Treatment Children Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome</brief_title>
	<detailed_description>PROVIGIL trademark Genelco , SA , license Cephalon , Inc .</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Disorders Excessive Somnolence</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>A boy girl age 6 16 year , inclusive Meet minimal criterion establish International Classification Sleep Disorders ( ICSD ) manual American Academy Sleep Medicine ( AASM ) OSAHS assess follow : *clinical history ; *have previous diagnosis OSAHS basis NPSG ( nocturnal polysomnogram ) and/or MSLT time screen visit . If patient current user CPAP ( continuous positive airway pressure ) therapy appropriately titrate CPAP , AHI ≥5 inclusion criterion applicable ; *NPSG ( nocturnal polysomnogram ) ( evaluate investigator ) rule sleep disorder ( ie , narcolepsy periodic limb movement sleep [ PLMs ] ) . Have ES ( CGIS [ Clinical Global Impression Severity ] ≥4 ) direct result inadequate sleep hygiene medical disorder Are good health determine medical psychiatric history , physical examination , ECG , clinical laboratory test For patient current user CPAP therapy appropriately titrate CPAP : average 5 apneic/hypopneic episode per hour nocturnal sleep , assess NPSG baseline visit ( AHI [ apnea/hypopnea index ] ≥5 ) Are currently user CPAP therapy try tolerated current standard care OSAHS continue residual sleepiness ( ie , patient comply CPAP use , patient unable tolerate comply CPAP therapy , patient surgical removal tonsil adenoid surgery warrant , patient attempt ongoing weight loss program ) Have O2 saturation least 85 % , base investigator 's assessment patient 's health Have blood pressure value great 5th percentile less 95th percentile age National High Blood Pressure Education Program guideline blood pressure level boys girl age 6 16 year Girls post menarche sexually active must negative urine pregnancy test prior baseline visit , must use medically acceptable method birth control , must agree continue use method duration study ( 30 day participation study ) . Acceptable method birth control include : barrier method spermicide ; steroidal contraceptive ( eg , oral , transdermal , implanted , inject ) conjunction barrier method ; intrauterine device ( IUD ) ; abstinence . Be able swallow placebo tablet size shape study drug tablet Negative UDS ( urine drug screen ) illicit drug , alcohol ( ethanol ) , stimulant , modafinil screening ; positive stimulant modafinil ( prescribe ES ) screen visit , UDS repeat washout period baseline visit Have parent legal guardian willing participate study Have disorder ( ) could consider primary cause ES ( eg , self induce sleep deprivation ) Have past present seizure disorder ( except history single febrile seizure ) , history psychosis , clinically significant head trauma ( eg , brain damage ) past neurosurgery Have periodic limb movement ( PLM ) arousal index great 5 ( ie , &gt; 5 PLMs arousal per hour sleep ) Have history suicide attempt , suicidal risk A clinically significant drug sensitivity stimulant amphetamine , dextroamphetamine , methylphenidate , pemoline ; and/or modafinil component Use prescription ( eg , clonidine , guanfacine ) nonprescription ( counter [ OTC ] ) medication , include dietary supplement psychoactive property ( eg , OTC medication supplement contain ephedrine [ ie , huang ephedra ] , pseudoephedrine , caffeine , phenylpropanolamine ) sedating property ( ie , antihistamine sedative hypnotic ) within 1 week baseline visit Use MAO ( monoamine oxidase ) inhibitor SSRIs ( selective serotonin reuptake inhibitor ) within 2 week baseline visit Received investigational drug ( except modafinil ) within 4 week baseline visit Any disorder could interfere drug absorption , distribution , metabolism , excretion ( include previous gastrointestinal surgery ) Active , clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematologic , neoplastic , endocrine , neurologic , immunodeficiency , pulmonary , major clinically significant disorder/disease Any clinically significant deviation normal range ( ) physical examination ECG finding , clinical laboratory test result ( ie , serum chemistry , hematology , urinalysis ) screen baseline visit ANC ( absolute neutrophil count ) low limit normal screen visit ( NOTE : If ANC low limit normal baseline visit , medical monitor consult continued eligibility study . ) Seated pulse outside range 60 115 bpm rest 5 minute A history alcohol , narcotic , substance abuse dependence define Diagnostic Statistical Manual American Psychiatric Association , 4th Edition ( DSM IV ) criteria A total daily intake 250 mg caffeine per day ( eg , approximately five 12 ounce caffeinated soda , 2.5 cup coffee tea , 12.5 ounce chocolate per day ) within 1 week baseline visit Pregnant lactating/nursing girl ; girl become pregnant study withdraw A clinically significant illness within 4 week baseline visit ; symptomatic clinically significant illness screen baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Pediatric Obstructive sleep Apnea</keyword>
	<keyword>Excessive sleepiness</keyword>
	<keyword>CPAP</keyword>
	<keyword>Pediatric OSAHS</keyword>
</DOC>